Overview
VTGN market data
Price History
VTGN price chart · 1M
- O
- 0.245100
- H
- 0.245100
- L
- 0.238400
- C
- 0.239900
- Vol
- 1,862.00
- Source
- US equities market feed
- Observed
- Aug 21, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $0.25
- Previous Close
- $0.24
- Day High
- $0.25
- Day Low
- $0.24
- 52 Week High
- $0.79
- 52 Week Low
- $0.20
- 7 Day Return
- -10.72%
- 30 Day Return
- +1.18%
- 90 Day Return
- -62.35%
- 1 Year Return
- -60.67%
- Daily Notional Volume
- $446.7 Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.83 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.44 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -5,487.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.20 – $5.14 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $11.6M · P/B 0.64 · P/S 9.13.
Company News
VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K EstimateBenzinga · Aug 14, 2026, 12:50 PM
8-K filing — Vistagen Therapeutics, Inc. (VTGN)SEC EDGAR · Aug 14, 2026, 12:40 PM
Vistagen Says Exploratory Phase 2 Repeat Dose Study Of Fasedienol Missed Statistical Significance On Primary Endpoint (p=0.2); Reports Nominal Significance In Very Severe Social Anxiety SubgroupBenzinga · Aug 6, 2026, 12:31 PM
Vistagen Therapeutics shares are trading higher after SRX Global announced that it has acquired a stake in the company.Benzinga · Aug 4, 2026, 2:34 PM
SRX Global Acquires Stake In Vistagen Therapeutics; Deal Terms Were UndisclosedBenzinga · Aug 4, 2026, 9:20 AM
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study MissBenzinga · Jun 30, 2026, 5:40 PM
Nasdaq Gains Over 300 Points; Chicago PMI Falls In JuneBenzinga · Jun 30, 2026, 4:10 PM
US Stocks Mixed; Home Prices Increase 1.1% In AprilBenzinga · Jun 30, 2026, 1:50 PM
Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jun 30, 2026, 12:20 PM
Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol Did Not Achieve Its Primary EndpointBenzinga · Jun 30, 2026, 12:15 PM